BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-06
205 industry Phase 2/3 trial readout(s) and 53 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-06 est. | P2 | XEME Biopharma Inc. | NCT02194751 Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | Follicular Lymphoma | unknown | 30 |
| 2024-06 est. | P1/P2 | Navitas Pharma | NCT02709031 Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium | Arterial Hypertension; Diabetes; Hypokalemia; Hyponatremia | withdrawn | |
| 2024-06 est. | P3 | Infant Bacterial Therapeutics | NCT03978000 IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study | Necrotizing Enterocolitis | active not recruiting | 2158 |
| 2024-06 est. | P3 | Torrent Pharmaceuticals Limited | NCT04507347 Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus | Chronic Stable Heart Failure | withdrawn | |
| 2024-06 est. | P2 | Anelixis Therapeutics, LLC | NCT04711226 Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | Type 1 Diabetes Mellitus | withdrawn | |
| 2024-06 est. | P2 | Sorrento Therapeutics, Inc. | NCT04809012 Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | Solid Tumor; Refractory Tumor; Relapsed Solid Tumor | withdrawn | |
| 2024-06 est. | P3 | GNT Pharma | NCT05041010 Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz | Ischemic Stroke | unknown | 496 |
| 2024-06 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05048160 A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm | Advanced Malignant Neoplasm | unknown | 272 |
| 2024-06 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05121350 A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epiru | Soft Tissue Sarcoma | unknown | 256 |
| 2024-06 est. | P2 | Philogen S.p.A. | NCT05329792 L19IL2/L19TNF in Skin Cancer Patients | BCC - Basal Cell Carcinoma; SCC - Squamous Cell Carcinoma; Merkel Cell Carcinoma; Keratoacanthoma of | unknown | 70 |
| 2024-06 est. | P1/P2 | Shanghai Miracogen Inc. | NCT05338957 A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | Advanced Malignant Solid Tumors | unknown | 30 |
| 2024-06 est. | P2 | Clinuvel Europe Limited CUVL | NCT05370235 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | Xeroderma Pigmentosum | unknown | 6 |
| 2024-06 est. | P2 | Sorrento Therapeutics, Inc. | NCT05372783 Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents | COVID-19 | withdrawn | |
| 2024-06 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05448599 A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | Acute Myeloid Leukemia; Myelodysplastic Syndrome | unknown | 120 |
| 2024-06 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05524194 6MW3511 in Patients With Advanced Solid Tumor | Solid Tumors | unknown | 272 |
| 2024-06 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT05598268 A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | Advanced Solid Tumor; Lung Cancer; Liver Cancer; Lymphoma; Mesothelioma of Pleura | unknown | 74 |
| 2024-06 est. | P3 | ITEL Telecomunicazioni Srl | NCT05622162 Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7 | Prostate Cancer; 18F- Fluorocholine; PSMA PET; Radiotherapy; Prostatectomy; Tumor of Prostate | unknown | 106 |
| 2024-06 est. | P2 | Bio Genuine (Shanghai) Biotech Co., Ltd. | NCT05738382 Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures | Assisted Reproductive Technology; Controlled Ovarian Hyperstimulation | unknown | 240 |
| 2024-06 est. | P3 | Blau Farmaceutica S.A. | NCT05790096 Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy | Breast Cancer | unknown | 60 |
| 2024-06 est. | P3 | Bio Genuine (Shanghai) Biotech Co., Ltd. | NCT05894135 Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis | Endometriosis; Moderate to Severe Endometriosis-associated Pain | unknown | 540 |
| 2024-06 est. | P3 | Neutec Ar-Ge San ve Tic A.Ş | NCT06040424 Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstru | COPD | unknown | 74 |
| 2024-06 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06144060 A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis | Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | unknown | 126 |
| 2024-06 est. | P2 | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | NCT06337071 A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine | Meningococcal Meningitis | unknown | 1200 |
| 2024-06 est. | P3 | Shin Poong Pharmaceutical Co. Ltd. | NCT06399042 Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis | Osteoarthritis | unknown | 297 |
| 2024-06-01 est. | P2 | Kenneth Krantz, MD, PhD | NCT04843787 SLV213 Treatment in Ambulatory COVID-19 Patients | Covid19 | unknown | 81 |
| 2024-06-01 est. | P2 | RemeGen Co., Ltd. | NCT05297552 A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | Muscle Invasive Bladder Carcinoma | unknown | 40 |
| 2024-06-01 est. | P1/P2 | Shanghai YingLi Pharmaceutical Co. Ltd. | NCT05457517 A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | Advanced Solid Tumors | unknown | 49 |
| 2024-06-02 | P1/P2 | BonusBio Group Ltd | NCT02842619 Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration | Bone Augmentation; Bone Grafts | completed | 27 |
| 2024-06-03 | P3 | Beijing Northland Biotech. Co., Ltd. | NCT04275323 Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) | Arterial Occlusive Disease; Ischemia; Ulcers; Peripheral Vascular Disease | completed | 302 |
| 2024-06-03 | P2 | AmMax Bio, Inc. | NCT05349643 A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | Pigmented Villonodular Synovitis; TGCT; Tenosynovial Giant Cell Tumor | completed | 20 |
| 2024-06-03 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06062030 Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy; | Colonoscopy | completed | 215 |
| 2024-06-04 | P2 | InflaRx GmbH IFRX | NCT04812535 Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. | SCC - Squamous Cell Carcinoma of Skin | terminated | 30 |
| 2024-06-04 | P2 | Hope Biosciences Research Foundation | NCT05116540 Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis | Multiple Sclerosis | completed | 24 |
| 2024-06-04 | P2 | Maruho Co., Ltd. | NCT05214794 An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis | Systemic Sclerosis | completed | 6 |
| 2024-06-04 | P3 | Merck Sharp & Dohme LLC MRK | NCT05224141 Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-768 | Small Cell Lung Carcinoma | active not recruiting | 460 |
| 2024-06-04 | P2 | argenx ARGX | NCT05225675 A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in A | Multifocal Motor Neuropathy | completed | 54 |
| 2024-06-04 | P2 | reMYND | NCT05478031 A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease | Alzheimer Disease | terminated | 14 |
| 2024-06-05 | P2 | Alector Inc. ALEC | NCT03987295 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Frontotemporal Dementia | completed | 33 |
| 2024-06-05 | P1/P2 | Vaccinex Inc. VCNX | NCT04381468 SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) | Alzheimer Disease | completed | 50 |
| 2024-06-05 | P2 | Istari Oncology, Inc. | NCT04479241 LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma; Brain Tumor | completed | 25 |
| 2024-06-05 | P3 | Novo Nordisk A/S NVO | NCT04560998 A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Diabetes Mellitus, Type 2; Peripheral Arterial Disease | completed | 792 |
| 2024-06-05 | P1/P2 | Precigen, Inc PGEN | NCT04724980 Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Papillomaviridae | active not recruiting | 38 |
| 2024-06-05 | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05055934 Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis | Psoriatic Arthritis | completed | 112 |
| 2024-06-05 | P2 | Nerre Therapeutics Ltd. | NCT05185089 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis | Cough; Idiopathic Pulmonary Fibrosis | completed | 80 |
| 2024-06-05 | P2 | Celon Pharma SA | NCT05278156 Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia | Schizophrenia | completed | 189 |
| 2024-06-05 | P2 | Inmune Bio, Inc. INMB | NCT05522387 An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Disease | terminated | 11 |
| 2024-06-05 | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT05619692 A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | Mild Cognitive Impairment; Mild Dementia; Alzheimer's Disease | completed | 174 |
| 2024-06-05 | P3 | Amgen AMGN | NCT05651711 A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | Atopic Dermatitis | completed | 726 |
| 2024-06-05 | P2 | Gan and Lee Pharmaceuticals, USA | NCT06256562 A Study of GZR18 Injection in Obese/Overweight Patients | Obesity; Overweight | completed | 340 |
| 2024-06-06 | P2/P3 | Serodus AS | NCT04881123 SER150 vs Placebo in Diabetic Kidney Disease | Diabetic Kidney Disease | completed | 20 |
| 2024-06-06 | P3 | Pfizer PFE | NCT04935879 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises | Sickle Cell Disease; Vaso-occlusive Pain Episode in Sickle Cell Disease; Vaso-occlusive Crisis | completed | 241 |
| 2024-06-06 | P2 | Kadmon, a Sanofi Company | NCT05305989 Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 | Chronic Graft-versus-host-disease | completed | 23 |
| 2024-06-07 | P2 | Nuvation Bio Inc. NUVB | NCT04395677 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Non Small Cell Lung Cancer | active not recruiting | 173 |
| 2024-06-07 | P3 | Bayer | NCT04736199 Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer | Prostatic Neoplasms | completed | 669 |
| 2024-06-07 | P1/P2 | Stratatech, a Mallinckrodt Company | NCT04765202 StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns | Full Thickness Thermal Burn | terminated | 13 |
| 2024-06-07 | P1/P2 | Elucida Oncology | NCT05001282 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Endometrial Cancer; Ovary Cancer; Ovary Neopla | terminated | 79 |
| 2024-06-07 | P2 | GlaxoSmithKline | NCT05630846 A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Ch | Measles; Mumps; Rubella; Chickenpox; Measles | completed | 801 |
| 2024-06-07 | P3 | Novo Nordisk A/S NVO | NCT05723835 A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 | SGA; Turner Syndrome; Noonan Syndrome; ISS | active not recruiting | 47 |
| 2024-06-07 | P3 | ModernaTX, Inc. | NCT06060457 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, | Respiratory Syncytial Virus | completed | 1900 |
| 2024-06-08 | P3 | H. Lundbeck A/S | NCT05064371 Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan | Migraine | completed | 160 |
| 2024-06-08 | P2 | GE Healthcare | NCT05636852 Altropane Dose for Imaging Patients With Suspected Parkinson's Disease | Parkinson Disease; Movement Disorders | terminated | 15 |
| 2024-06-09 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05016323 A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. | IgA Nephropathy | completed | 316 |
| 2024-06-09 | P3 | Shield Therapeutics | NCT05126901 Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-defic | Anemia; Iron-deficiency | completed | 65 |
| 2024-06-10 | P2 | Gyroscope Therapeutics Limited | NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 | Dry Age-related Macular Degeneration | terminated | 255 |
| 2024-06-10 | P3 | Eli Lilly and Company LLY | NCT06444165 Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis | Atopic Dermatitis | completed | 55 |
| 2024-06-11 | P3 | Merck Sharp & Dohme LLC MRK | NCT03924869 Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cel | Non-Small Cell Lung Cancer | terminated | 448 |
| 2024-06-11 | P3 | Kyntra Bio KYNB | NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRIN | Pancreatic Cancer Non-resectable | completed | 284 |
| 2024-06-11 | P3 | AbbVie ABBV | NCT04437433 A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | Chronic Migraine; Episodic Migraine | completed | 186 |
| 2024-06-11 | P1/P2 | SonALAsense, Inc. | NCT05370508 A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | Recurrent GBM | terminated | 8 |
| 2024-06-11 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05702073 To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. | Type 2 Diabetes Mellitus | completed | 423 |
| 2024-06-11 | P1/P2 | Dawonmedax Co., Ltd. | NCT05737212 Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | Recurrent High-grade Glioma; Recurrent Glioblastoma; Recurrent Anaplastic Astrocytoma; Recurrent Ana | terminated | 7 |
| 2024-06-11 | P3 | Aldeyra Therapeutics, Inc. ALDX | NCT06389214 A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease | Dry Eye Disease | completed | 132 |
| 2024-06-12 | P3 | Takeda TAK | NCT02620046 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease | Colitis, Ulcerative; Crohn's Disease | completed | 746 |
| 2024-06-12 | P2 | Strata Oncology | NCT05097599 StrataPATH™ (Precision Indications for Approved Therapies) | Cancer; Advanced Solid Tumor | terminated | 11 |
| 2024-06-12 | P3 | Biocon Biologics UK Ltd | NCT05345691 Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis | Postmenopausal Women With Osteoporosis | completed | 479 |
| 2024-06-12 | P2 | Celldex Therapeutics CLDX | NCT05405660 A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | Chronic Inducible Urticaria | completed | 196 |
| 2024-06-12 | P3 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT05680155 A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients | T2DM; Type 2 Diabetes Mellitus | completed | 211 |
| 2024-06-12 | P2 | ViiV Healthcare | NCT06214052 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 | HIV Infections | completed | 22 |
| 2024-06-13 | P3 | AEterna Zentaris | NCT04786873 A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is | Growth Hormone Deficiency | completed | 101 |
| 2024-06-13 | P2 | Inversago Pharma Inc. | NCT05891834 Study of INV-202 in Patients With Obesity and Metabolic Syndrome | Obesity; Metabolic Syndrome | completed | 243 |
| 2024-06-14 | P1/P2 | Eli Lilly and Company LLY | NCT04145349 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Desmoplastic Small Round Cell Tumor | completed | 30 |
| 2024-06-14 | P2/P3 | Anavex Life Sciences Corp. AVXL | NCT04314934 OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | Alzheimer Disease | completed | 300 |
| 2024-06-14 | P3 | Lupin Ltd. | NCT04624750 Open Label Study in Adolescents and Children With Myotonic Disorders | Myotonic Dystrophy | completed | 12 |
| 2024-06-14 | P2/P3 | ModernaTX, Inc. | NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | SARS-CoV-2 | completed | 4328 |
| 2024-06-14 | P2 | Atossa Therapeutics, Inc. ATOS | NCT05068388 Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density | Breast Density | completed | 240 |
| 2024-06-14 | P2/P3 | Oui Therapeutics, Inc. | NCT05144685 A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic | Suicide, Attempted; Suicidal Ideation | terminated | 356 |
| 2024-06-14 | P1/P2 | InventisBio Co., Ltd | NCT05492045 A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | NSCLC | terminated | 22 |
| 2024-06-14 | P2 | Aventi Biotechnology Inc. | NCT06788236 Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly | Sarcopenia | terminated | 100 |
| 2024-06-15 est. | P2 | Shanghai Henlius Biotech | NCT04984369 The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | CRC | unknown | 50 |
| 2024-06-15 est. | P3 | Eiger BioPharmaceuticals | NCT05070364 Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV | Hepatitis Delta Virus | unknown | 150 |
| 2024-06-15 | P2 | Cardiol Therapeutics Inc. CRDL | NCT05494788 Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) | Recurrent Pericarditis | completed | 27 |
| 2024-06-15 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05496569 TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | Dedifferentiated Liposarcoma | terminated | 26 |
| 2024-06-15 est. | P2/P3 | Shanghai Henlius Biotech | NCT05633433 Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 | SARS-CoV-2 Infection | unknown | 1550 |
| 2024-06-15 est. | P2 | Tarsus Pharmaceuticals, Inc. TARS | NCT06054217 Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex | Meibomian Gland Dysfunction; Demodex Infestation of Eyelid; Blepharitis; Demodectic Blepharitis | unknown | 36 |
| 2024-06-16 | P2 | Takeda TAK | NCT05020015 A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | active not recruiting | 27 |
| 2024-06-17 | P3 | Pfizer PFE | NCT04370054 Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults | Hemophilia A | active not recruiting | 77 |
| 2024-06-17 | P2 | Paratek Pharmaceuticals Inc | NCT04922554 Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) | Mycobacterium Infections, Nontuberculous; Mycobacterium Abscessus Infection; Nontuberculous Mycobact | completed | 66 |
| 2024-06-17 | P2/P3 | PTC Therapeutics PTC | NCT05269355 A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | Leiomyosarcoma | terminated | 359 |
| 2024-06-17 | P3 | LEO Pharma | NCT05295732 The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis | Ichthyosis | completed | 153 |
| 2024-06-17 | P2 | Bristol-Myers Squibb BMY | NCT05613088 A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritonea | Neoplasms, Ovarian | terminated | 106 |
| 2024-06-17 | P3 | Otsuka Beijing Research Institute | NCT05667623 To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD | Atopic Dermatitis (AD) | completed | 270 |
| 2024-06-17 | P2 | Photozig, Inc. | NCT05979922 Mindfulness-based Cognitive Coping for ADRD Caregivers | Caregiver Stress | completed | 174 |
| 2024-06-17 | P2 | Enanta Pharmaceuticals, Inc ENTA | NCT06170242 A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model | RSV Infection | completed | 142 |
| 2024-06-17 | P2/P3 | Hipra Scientific, S.L.U | NCT06181292 Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine | SARS-CoV2 Infection | completed | 913 |
| 2024-06-17 | P3 | Shanghai Auzone Biological Technology Co., Ltd. | NCT06648304 Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 614 |
| 2024-06-17 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT06720025 Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis | Anemia | completed | 100 |
| 2024-06-18 | P1/P2 | Hutchmed HCM | NCT04577963 A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Triple Negative Breast Cancer; Endometrial Cancer; Solid Tumor, Unspecified, Adult; Colorectal Cance | terminated | 52 |
| 2024-06-18 | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT04923906 Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | Non-small Cell Lung Cancer | active not recruiting | 624 |
| 2024-06-18 | P2 | Yamo Pharmaceuticals LLC | NCT05067582 A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder | Autism Spectrum Disorder; Autism | completed | 58 |
| 2024-06-19 | P2 | Pfizer PFE | NCT04607837 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis | Ulcerative Colitis | completed | 234 |
| 2024-06-19 | P3 | Hoffmann-La Roche | NCT04740918 A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positiv | Metastatic Breast Cancer | terminated | 96 |
| 2024-06-19 | P2 | AEON Biopharma, Inc. AEON | NCT04845178 Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults | Migraine | completed | 797 |
| 2024-06-19 | P2 | Advantage Silver Dental Arrest, LLC | NCT04947527 Efficacy and Safety Evaluation of Anti-Caries Varnish | Dental Caries in Children | completed | 274 |
| 2024-06-19 | P3 | OPKO Health, Inc. OPK | NCT05543928 Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism | Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Vitamin d Deficiency; Secondary Hyperp | terminated | 2 |
| 2024-06-19 | P3 | Janssen Research & Development, LLC | NCT06095102 A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles | Plaque Psoriasis | active not recruiting | 311 |
| 2024-06-20 | P3 | Biocad | NCT05732805 A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresecta | Melanoma; Melanoma (Skin); Melanoma Stage III; Melanoma Stage IV; Melanoma Unresectable; Melanoma Me | active not recruiting | 270 |
| 2024-06-20 | P3 | Novartis Pharmaceuticals NVS | NCT05763875 Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. | Hypercholesterolemia | completed | 350 |
| 2024-06-20 | P2 | Hoffmann-La Roche | NCT05775289 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Ce | Non-small Cell Lung Cancer | completed | 182 |
| 2024-06-20 | P3 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT05813795 A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity | Weight Management | completed | 664 |
| 2024-06-20 | P2 | KEB Nutraceuticals USA, Inc. | NCT06719115 A Clinical Trial to Investigate the Safety and Efficacy of D-Mannose on Symptoms of Urinary Tract Infection in Women | Urinary Tract Infection(UTI) | completed | 30 |
| 2024-06-20 | P3 | Kyungdong Pharmaceutical Co., Ltd. | NCT07116863 A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension | Essential Hypertension | completed | 286 |
| 2024-06-21 | P2/P3 | Incyte Corporation INCY | NCT02763319 A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory | Diffuse Large B-cell Lymphoma | completed | 453 |
| 2024-06-21 | P1/P2 | invoX Pharma Limited | NCT03440437 A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck | terminated | 80 |
| 2024-06-21 | P2 | Merck Sharp & Dohme LLC MRK | NCT04624243 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008) | Schizophrenia | completed | 499 |
| 2024-06-21 | P1/P2 | Astellas Pharma Global Development, Inc. | NCT04837196 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Advanced Malignancies; Advanced Cancer | completed | 24 |
| 2024-06-21 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis (UC) | completed | 150 |
| 2024-06-21 | P2 | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | NCT05935332 Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma | Asthma | terminated | 38 |
| 2024-06-21 | P1/P2 | Akeso | NCT06035354 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis | Atopic Dermatitis | completed | 427 |
| 2024-06-23 | P3 | AstraZeneca AZN | NCT03706690 A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | Carcinoma, Non-Small-Cell Lung | active not recruiting | 407 |
| 2024-06-24 | P2 | Novartis Pharmaceuticals NVS | NCT04814368 A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee O | Knee Osteoarthritis | terminated | 23 |
| 2024-06-24 | P3 | Eli Lilly and Company LLY | NCT04975308 A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | Breast Neoplasms; Neoplasm Metastasis | active not recruiting | 874 |
| 2024-06-24 | P2 | Shanghai HEP Pharmaceutical Co., Ltd. | NCT05244057 A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients | Chronic Hepatitis B | completed | 8 |
| 2024-06-24 | P3 | Chiesi Farmaceutici S.p.A. | NCT05292586 A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or | Asthma | completed | 1377 |
| 2024-06-24 est. | P2 | Bristol-Myers Squibb BMY | NCT05496192 A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | Melanoma; Urothelial Carcinoma | withdrawn | |
| 2024-06-24 | P2 | Smilebiotek Zhuhai Limited | NCT05562219 QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration | Intermediate Age-Related Macular Degeneration | completed | 120 |
| 2024-06-24 | P3 | ModernaTX, Inc. | NCT05827978 Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Seasonal Influenza | completed | 8411 |
| 2024-06-24 | P2 | ViiV Healthcare | NCT06039579 Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults | HIV Infections | completed | 44 |
| 2024-06-25 | P1/P2 | Gyroscope Therapeutics Limited | NCT03846193 FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD | Dry Age-related Macular Degeneration; Macular Degeneration; Retinal Disease; Eye Diseases; Retinal D | terminated | 56 |
| 2024-06-25 | P3 | Pfizer PFE | NCT04006457 Long-Term PF-06651600 for the Treatment of Alopecia Areata | Alopecia Areata | completed | 1057 |
| 2024-06-25 | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04643405 APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | Advanced Pancreatic Cancer | terminated | 21 |
| 2024-06-25 | P2 | Resilient Pharmaceuticals | NCT04784143 Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | PTSD | terminated | 26 |
| 2024-06-25 | P1/P2 | Laekna Limited | NCT05383482 Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | Solid Tumor; NSCLC; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gastric and Gastroesopha | completed | 22 |
| 2024-06-25 | P3 | Keymed Biosciences Co.Ltd | NCT05436275 A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2) | Chronic Rhinosinusitis With Nasal Polyposis | completed | 180 |
| 2024-06-25 | P2 | SOM Innovation Biotech SA | NCT05475483 Efficacy and Safety on SOM3355 in Huntington's Disease Chorea | Huntington Chorea | completed | 139 |
| 2024-06-25 | P2 | Redx Pharma Ltd | NCT05570058 Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis | IPF; Fibrosis | active not recruiting | 48 |
| 2024-06-25 | P2 | GlaxoSmithKline | NCT05921903 A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an | Respiratory Syncytial Virus Infections | completed | 386 |
| 2024-06-26 | P3 | Pharmacyclics LLC. | NCT03112174 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) | Mantle-Cell Lymphoma | completed | 366 |
| 2024-06-26 | P3 | Eli Lilly and Company LLY | NCT04752332 A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer | Breast Neoplasms | terminated | 111 |
| 2024-06-26 | P3 | Apellis Pharmaceuticals, Inc. | NCT05067127 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | C3G; IC-MPGN; C3 Glomerulopathy; C3 Glomerulonephritis; Complement 3 Glomerulopathy; Complement 3 Gl | completed | 124 |
| 2024-06-26 | P2 | Novartis Pharmaceuticals NVS | NCT05124925 Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. | Sjogren Syndrome | completed | 21 |
| 2024-06-26 | P2 | Janssen Research & Development, LLC | NCT05201794 A Study of JNJ-64281802 for the Prevention of Dengue Infection | Dengue | terminated | 1595 |
| 2024-06-26 | P2 | Gilead Sciences GILD | NCT05330429 Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC | Metastatic Colorectal Cancer | terminated | 77 |
| 2024-06-26 | P2 | Tarsus Pharmaceuticals, Inc. TARS | NCT05387083 A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 | Healthy Volunteer | completed | 30 |
| 2024-06-26 | P3 | Pfizer PFE | NCT05561140 Resolution of Sickle Cell Leg Ulcers With Voxelotor | Sickle Cell Disease; Leg Ulcers | terminated | 88 |
| 2024-06-26 | P2 | Berlin Cures GmbH | NCT05911009 To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID | Long Covid | completed | 119 |
| 2024-06-26 | P3 | POLYSAN Scientific & Technological Pharmaceutical Company | NCT05935787 Cytoflavin in the Complex Rehabilitation of Stroke Patients | Stroke | completed | 240 |
| 2024-06-26 | P2 | Zydus Lifesciences Limited | NCT05981040 Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | completed | 24 |
| 2024-06-27 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT04408755 Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Agitation in Patients With Dementia of the Alzheimer's Type | terminated | 184 |
| 2024-06-27 | P2 | Neuraptive Therapeutics Inc. | NCT04572906 Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries | Peripheral Nerve Injuries | completed | 51 |
| 2024-06-27 | P3 | Octapharma | NCT05523297 Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery | Bleeding Cardiac Surgery Patients | completed | 420 |
| 2024-06-27 | P2 | Ventyx Biosciences, Inc | NCT05688852 VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease | Crohn Disease | terminated | 107 |
| 2024-06-27 | P1/P2 | Urica Therapeutics Inc. | NCT06056570 Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia | Gout; Hyperuricemia | completed | 20 |
| 2024-06-28 | P3 | AbbVie ABBV | NCT03271489 Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fi | Heavy Menstrual Bleeding; Uterine Fibroids | completed | 478 |
| 2024-06-28 | P2 | Tesaro, Inc. | NCT03574779 A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | Ovarian Neoplasms | completed | 77 |
| 2024-06-28 | P3 | Merck Sharp & Dohme LLC MRK | NCT03833167 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYN | Carcinoma, Squamous Cell | terminated | 450 |
| 2024-06-28 | P3 | Hinova Pharmaceuticals USA, Inc. | NCT03850795 HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Prostate Cancer Metastatic; Castration-resistant Prostate Cancer | terminated | 104 |
| 2024-06-28 | P3 | AbbVie ABBV | NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) | Parkinson Disease | completed | 529 |
| 2024-06-28 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT04464564 Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Agitation in Patients With Dementia of the Alzheimer's Type | terminated | 241 |
| 2024-06-28 | P1/P2 | Akeso | NCT04900363 A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | Non-small Cell Lung Cancer | completed | 108 |
| 2024-06-28 | P3 | GlaxoSmithKline | NCT04915755 Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene M | Neoplasms, Breast | active not recruiting | 40 |
| 2024-06-28 est. | P1/P2 | Genor Biopharma Co., Ltd. | NCT04923048 A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | B Cell NHL; CLL | unknown | 460 |
| 2024-06-28 | P2 | Neurocrine Biosciences NBIX | NCT05182476 Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia | Schizophrenia | terminated | 216 |
| 2024-06-28 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05255237 Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata | Alopecia Areata | completed | 315 |
| 2024-06-28 | P2 | Gan and Lee Pharmaceuticals, USA | NCT06199505 A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM | Type 2 Diabetes | completed | 153 |
| 2024-06-28 | P2 | Shanghai Ark Biopharmaceutical Co., Ltd. | NCT06942299 A Study of AK0529 in Adults Patients Hospitalized With RSV Infection | Respiratory Syncytial Virus Infections | completed | 25 |
| 2024-06-28 | P2 | Tesaro, Inc. | NCT06964165 A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage I | Ovarian Neoplasms | terminated | 36 |
| 2024-06-29 | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT05052567 CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer | completed | 50 |
| 2024-06-29 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06009393 Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | completed | 26 |
| 2024-06-29 | P3 | AstraZeneca AZN | NCT06245551 A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in | Asthma, Exercise-Induced | completed | 64 |
| 2024-06-30 | P2 | Teclison Ltd. | NCT03145558 TATE Versus TACE in Intermediate Stage HCC | Carcinoma, Hepatocellular | terminated | 6 |
| 2024-06-30 est. | P1/P2 | Longeveron Inc. LGVN | NCT03525418 Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) | HLHS | unknown | 10 |
| 2024-06-30 est. | P2 | United BioPharma UTHR | NCT03595995 A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 | Genital Herpes | unknown | 80 |
| 2024-06-30 est. | P3 | S.L.A. Pharma AG | NCT03806426 Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis | Familial Adenomatous Polyposis | unknown | 204 |
| 2024-06-30 | P3 | Cordgenics, LLC | NCT03949283 Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | Recurrent Ovarian Carcinoma; Platinum-resistant Ovarian Cancer | active not recruiting | 150 |
| 2024-06-30 | P3 | TJ Biopharma Co., Ltd. | NCT03952091 TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma in Relapse; Refractory Multiple Myeloma | completed | 289 |
| 2024-06-30 est. | P2 | ISA Pharmaceuticals | NCT04398524 A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | Squamous Cell Carcinoma of the Oropharynx | unknown | 65 |
| 2024-06-30 est. | P2 | UBP Greater China (Shanghai) Co., Ltd | NCT04404049 The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | HIV-1-infection | unknown | 39 |
| 2024-06-30 est. | P1/P2 | Tayu Huaxia Biotech Medical Group Co., Ltd. | NCT04458389 A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas | Locally Advanced /Metastatic Solid Tumors; Relapsed or Refractory Lymphomas | unknown | 268 |
| 2024-06-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT04485052 Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | Acute Myeloid Leukemia | suspended | 222 |
| 2024-06-30 | P3 | Swedish Orphan Biovitrum | NCT05001737 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | Macrophage Activation Syndrome; Secondary Hemophagocytic Lymphohistiocytosis; Still Disease; Systemi | completed | 33 |
| 2024-06-30 est. | P2 | Shanghai Henlius Biotech | NCT05092815 The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation | Langerhans Cell Histiocytosis; Erdheim-Chester Disease; LCH; ECD | unknown | 25 |
| 2024-06-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT05102292 The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | Anaplastic Thyroid Cancer; ATC | unknown | 25 |
| 2024-06-30 | P1/P2 | Cardix Therapeutics LLC | NCT05117346 An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia | Bradycardia | completed | 20 |
| 2024-06-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT05145907 Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma | unknown | 133 |
| 2024-06-30 | P3 | IBSA Institut Biochimique SA | NCT05171673 Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury | Soft Tissue Injuries | completed | 151 |
| 2024-06-30 est. | P2 | Shanghai Henlius Biotech | NCT05221658 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC | ESCC or Esophageal Adenosquamous Carcinoma | unknown | 60 |
| 2024-06-30 est. | P2 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT05284812 A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) | Tuberculosis | suspended | 200 |
| 2024-06-30 est. | P1/P2 | Genor Biopharma Co., Ltd. | NCT05332574 A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | NSCLC; Other Solid Tumors | unknown | 120 |
| 2024-06-30 est. | P2 | MitoImmune Therapeutics | NCT05493800 Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT | Oral Mucositis; Lymphoma; Multiple Myeloma; Hematologic Cancer | unknown | 60 |
| 2024-06-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05685420 Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia | Immune Thrombocytopenia | unknown | 117 |
| 2024-06-30 | P2/P3 | Hoffmann-La Roche | NCT05694013 Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice | Cancer | terminated | 49 |
| 2024-06-30 est. | P2 | Connect Biopharm LLC CNTB | NCT05905133 A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD | Atopic Dermatitis | unknown | 360 |
| 2024-06-30 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05964790 Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia | Schizophrenia | unknown | 112 |
| 2024-06-30 est. | P2 | NeuroRx, Inc. | NCT06128213 NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis | Urinary Tract Infections; Pyelonephritis | unknown | 13 |
| 2024-06-30 est. | P3 | ORA, Inc. | NCT06178679 Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED) | Dry Eye Disease | unknown | 175 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.